Trials / Recruiting
RecruitingNCT05868707
OH2 Injection in Melanoma
To Evaluate a Phase III Study of OH2 Versus Investigator-selected Salvage Chemotherapy or Best Supportive Care in Melanoma Patients Who Had Failed Standard Therapy
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 340 (estimated)
- Sponsor
- Binhui Biopharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy of OH2 injection in patients with unresectable or metastatic melanoma who have failed at least second-line standard therapy, using investigator-selected salvage chemotherapy or best supportive care (BSC) as controls.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OH2 | Oncolytic Type 2 Herpes Simplex Virus |
| DRUG | Salvage chemotherapy or best supportive care | single or combined, including but not limited to dacarbazine, temozolomide, taxoid, or platinum |
Timeline
- Start date
- 2023-03-08
- Primary completion
- 2026-03-01
- Completion
- 2027-03-01
- First posted
- 2023-05-22
- Last updated
- 2025-07-25
Locations
30 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05868707. Inclusion in this directory is not an endorsement.